$LMND
Lemonade Inc Stock $lmnd

$lmnd Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000169142124000108 Filed on July 31, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$136.6M	$122.0M
YoY Change	19.3%	16.63%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$82.80M	$66.60M
YoY Change	35.07%	20.0%
% of Gross Profit
Research & Development	$21.90M	$21.20M
YoY Change	0.46%	-12.03%
% of Gross Profit
Depreciation & Amortization	$5.100M	$5.200M
YoY Change	2.0%	1.96%
% of Gross Profit
Operating Expenses	$104.7M	$87.80M
YoY Change	25.99%	-48.5%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$65.80M	-$55.10M
YoY Change	10.4%	-16.39%
Income Tax	$1.900M	$2.100M
% Of Pretax Income
Net Earnings	-$67.70M	-$57.20M
YoY Change	10.08%	-14.88%
Net Earnings / Revenue	-49.56%	-46.89%
Basic Earnings Per Share	-$0.95	-$0.81
Diluted Earnings Per Share	-$0.95	-$0.81
COMMON SHARES
Basic Shares Outstanding	71.03M shares	70.50M shares
Diluted Shares Outstanding	71.14M shares	70.72M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$329.8M	$343.2M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$16.00M	$16.30M
YoY Change	-8.05%	-14.21%
Goodwill	$19.00M	$19.00M
YoY Change	0.0%	0.0%
Intangibles	$15.80M	$18.20M
YoY Change	-37.3%	-33.82%
Long-Term Investments	$640.8M	$581.2M
YoY Change	-9.34%	-22.31%
Other Assets	$8.000M	$6.500M
YoY Change	25.0%	25.0%
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$1.823B	$1.714B
YoY Change	10.65%	6.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.000M	$600.0K
YoY Change	-62.96%	-14.29%
Accrued Expenses	$56.50M	$51.40M
YoY Change	7.41%	-6.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$90.30M	$600.0K
YoY Change	14.45%	-99.18%
LONG-TERM LIABILITIES
Long-Term Debt	$67.40M	$43.90M
YoY Change	775.32%
Other Long-Term Liabilities	$10.70M	$121.2M
YoY Change	148.84%	1560.27%
Total Long-Term Liabilities	$78.10M	$165.1M
YoY Change	550.83%	2161.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$90.30M	$600.0K
Total Long-Term Liabilities	$78.10M	$165.1M
Total Liabilities	$1.230B	$1.079B
YoY Change	33.59%	28.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.269B	-$1.201B
YoY Change	20.36%	20.99%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$593.0M	$635.2M
YoY Change
Total Liabilities & Shareholders Equity	$1.823B	$1.714B
YoY Change	10.65%	6.25%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$67.70M	-$57.20M
YoY Change	10.08%	-14.88%
Depreciation, Depletion And Amortization	$5.100M	$5.200M
YoY Change	2.0%	1.96%
Cash From Operating Activities	$16.30M	-$11.70M
YoY Change	-358.73%	-76.74%
INVESTING ACTIVITIES
Capital Expenditures	$2.200M	$1.500M
YoY Change	0.0%	-21.05%
Acquisitions
YoY Change
Other Investing Activities	-$51.90M	$62.80M
YoY Change	-213.07%	-797.78%
Cash From Investing Activities	-$54.10M	$61.30M
YoY Change	-223.8%	-662.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	23.60M	15.60M
YoY Change	198.73%	7700.0%
NET CHANGE
Cash From Operating Activities	16.30M	-11.70M
Cash From Investing Activities	-54.10M	61.30M
Cash From Financing Activities	23.60M	15.60M
Net Change In Cash	-14.20M	65.20M
YoY Change	-131.35%	-206.89%
FREE CASH FLOW
Cash From Operating Activities	$16.30M	-$11.70M
Capital Expenditures	$2.200M	$1.500M
Free Cash Flow	$14.10M	-$13.20M
YoY Change	-265.88%	-74.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71002862	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71002862	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70502856	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70502856	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69434971	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69434971	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000000.0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4600000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	92200000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4400000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	866800000	usd
CY2023Q1	lmnd	Stock Issued During Period Value Stock Options And Restricted Stock Exercised StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockExercised	100000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15400000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-65800000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5300000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-104500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-133000000.0	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10200000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30300000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30200000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2800000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5300000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3900000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	300000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Increase Decrease In Premiums Receivable IncreaseDecreaseInPremiumsReceivable	43000000.0	usd
	us-gaap	Increase Decrease In Premiums Receivable IncreaseDecreaseInPremiumsReceivable	22100000	usd
	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	64600000	usd
	us-gaap	Increase Decrease In Reinsurance Recoverable IncreaseDecreaseInReinsuranceRecoverable	7600000	usd
	us-gaap	Increase Decrease In Prepaid Reinsurance Premiums IncreaseDecreaseInPrepaidReinsurancePremiums	21900000	usd
	us-gaap	Increase Decrease In Prepaid Reinsurance Premiums IncreaseDecreaseInPrepaidReinsurancePremiums	2100000	usd
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	2400000	usd
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	-300000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-26400000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-5200000	usd
	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	19900000	usd
	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	-600000	usd
	us-gaap	Increase Decrease In Unearned Premiums Net IncreaseDecreaseInUnearnedPremiumsNet	-43900000	usd
	us-gaap	Increase Decrease In Unearned Premiums Net IncreaseDecreaseInUnearnedPremiumsNet	-27900000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-400000	usd
	us-gaap	Increase Decrease In Reinsurance Payables IncreaseDecreaseInReinsurancePayables	28500000	usd
	us-gaap	Increase Decrease In Reinsurance Payables IncreaseDecreaseInReinsurancePayables	-6700000	usd
	lmnd	Increase Decrease In Deferred Ceding Commissions IncreaseDecreaseInDeferredCedingCommissions	4900000	usd
	lmnd	Increase Decrease In Deferred Ceding Commissions IncreaseDecreaseInDeferredCedingCommissions	1900000	usd
	lmnd	Increase Decrease In Ceded Premiums Payable IncreaseDecreaseInCededPremiumsPayable	6400000	usd
	lmnd	Increase Decrease In Ceded Premiums Payable IncreaseDecreaseInCededPremiumsPayable	800000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	21600000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41500000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-96700000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	44000000.0	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	63200000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	219600000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	216000000.0	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	41700000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52200000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	125700000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	218000000.0	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	39700000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	10700000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	300000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29100000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	300000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1600000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-700000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	78200000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-92700000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271500000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	286500000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	349700000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	193800000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1200000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	300000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1300000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Nature of the Business</span><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lemonade, Inc. is a public benefit corporation organized under Delaware law on June 17, 2015. It provides certain personnel, facilities and services to each of its subsidiaries (together with Lemonade, Inc., the “Company”), all of which are 100% owned, directly or indirectly, by Lemonade, Inc. For the list of the Company's US and EU subsidiaries and for more complete descriptions and discussions, see Note 1 - Nature of the Business, of the audited consolidated financial statements and related notes thereto for the year ended December 31, 2023 as included in the Company's Annual Report on Form 10-K (the "Annual Report on Form 10-K").</span></div>
	us-gaap	Subsidiary Or Equity Method Investee Cumulative Percentage Ownership After All Transactions SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions	1
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries and a variable interest entity for which the Company is deemed to be the primary beneficiary. All material intercompany transactions and balances have been eliminated upon consolidation. All foreign currency amounts in the condensed consolidated statement of operations and comprehensive loss have been translated using an average rate for the reporting period. All foreign currency balances in the condensed consolidated balance sheet have been translated using the spot rate at the end of the reporting period. All figures expressed, except share amounts, are in U.S. dollars in millions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk and Uncertainties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lemonade, Inc. conducts certain of its operations in Israel. The evolving conflict in Israel and surrounding region has increased global economic and political uncertainty. There is still uncertainty regarding the extent to which the war and its broader macroeconomic implications will impact our operations in Israel. The Company will continue to evaluate the extent to which this may impact our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div>In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of its financial position and its results of operations, changes in stockholders’ equity and cash flows. The condensed consolidated balance sheet at December 31, 2023 was derived from the audited annual financial statements and does not contain all of the footnote disclosures from the audited annual financial statements of the Company. The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the fiscal year ended December 31, 2023 as included in the Company’s Annual Report on Form 10-K
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates estimates, including those related to contingent assets and liabilities as of the date of the consolidated financial statements as well as the reported amounts of revenue and expense during the reporting period. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates reflected in the Company’s condensed consolidated financial statements include, but are not limited to, reserves for loss and loss adjustment expense, reinsurance recoverable on unpaid losses</span> and valuation allowance on deferred tax assets
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	343200000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	264500000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	6500000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	7000000.0	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	349700000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	271500000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	540500000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	300000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3600000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	537200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	632000000.0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1700000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6300000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	627400000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3600000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6300000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis	175500000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	173900000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis	365000000.0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	363300000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Six Through Ten Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenAmortizedCostBasis	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Six Through Ten Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearSixThroughTenFairValue	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Rolling After Year Ten Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenAmortizedCostBasis	0	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Maturities Rolling After Year Ten Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingAfterYearTenFairValue	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	540500000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	537200000	usd
CY2024Q2	us-gaap	Gross Investment Income Operating GrossInvestmentIncomeOperating	8200000	usd
CY2023Q2	us-gaap	Gross Investment Income Operating GrossInvestmentIncomeOperating	5700000	usd
	us-gaap	Gross Investment Income Operating GrossInvestmentIncomeOperating	15900000	usd
	us-gaap	Gross Investment Income Operating GrossInvestmentIncomeOperating	10800000	usd
CY2024Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	100000	usd
CY2023Q2	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	100000	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	200000	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	200000	usd
CY2024Q2	us-gaap	Net Investment Income NetInvestmentIncome	8100000	usd
CY2023Q2	us-gaap	Net Investment Income NetInvestmentIncome	5600000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	15700000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	10600000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	100000	usd
CY2024Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	100000	usd
CY2023Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-100000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-100000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	213700000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1100000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	167900000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2500000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	381600000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	3600000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	168600000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1400000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	236200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	4900000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	404800000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	6300000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	241	security
CY2024Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2500000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	4900000	usd
	us-gaap	Financing Receivable Excluding Accrued Interest Allowance For Credit Loss Period Increase Decrease FinancingReceivableExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2024Q2	us-gaap	Financing Receivable Excluding Accrued Interest Allowance For Credit Loss Period Increase Decrease FinancingReceivableExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2024Q2	us-gaap	Restricted Investments RestrictedInvestments	84500000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	537200000	usd
CY2024Q2	us-gaap	Short Term Investments ShortTermInvestments	44000000.0	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	581200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	627400000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	45800000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	673200000	usd
CY2023Q4	lmnd	Warrants And Rights Outstanding Fair Value Disclosure WarrantsAndRightsOutstandingFairValueDisclosure	100000	usd
CY2024Q2	lmnd	Warrants And Rights Outstanding Fair Value Disclosure WarrantsAndRightsOutstandingFairValueDisclosure	100000	usd
CY2023Q4	lmnd	Warrants And Rights Outstanding Fair Value Disclosure WarrantsAndRightsOutstandingFairValueDisclosure	100000	usd
CY2024Q2	lmnd	Warrants And Rights Outstanding Fair Value Disclosure WarrantsAndRightsOutstandingFairValueDisclosure	100000	usd
	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity in the liability for unpaid loss and loss adjustment expense ("LAE") for the six months ended June 30, 2024 and 2023 ($ in millions):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.660%"><tr><td style="width:1.0%"></td><td style="width:69.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.228%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid loss and LAE at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">262.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Reinsurance recoverable at beginning of period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unpaid loss and LAE at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Add: Incurred loss and LAE, net of reinsurance, related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total incurred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deduct: Paid loss and LAE, net of reinsurance, related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid loss and LAE, net of reinsurance recoverable, at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance recoverable at end of period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid loss and LAE, gross of reinsurance recoverable, at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">282.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Reinsurance recoverable in this table includes only ceded unpaid loss and LAE.</span></div>
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	262300000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	256200000	usd
CY2023Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	120200000	usd
CY2022Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	124600000	usd
CY2023Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	142100000	usd
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	131600000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	145000000.0	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	140800000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-8600000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-1300000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	136400000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	139500000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	82100000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	75000000.0	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	51900000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	59700000	usd
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	134000000.0	usd
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	134700000	usd
CY2024Q2	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	144500000	usd
CY2023Q2	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	136400000	usd
CY2024Q2	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	137700000	usd
CY2023Q2	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	119200000	usd
CY2024Q2	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	282200000	usd
CY2023Q2	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	255600000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-8600000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-1300000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-8600000	usd
CY2022Q3	us-gaap	Contracts In Force Subject To Participation Through Reinsurance Percentage ContractsInForceSubjectToParticipationThroughReinsurancePercentage	0.55
CY2023Q3	us-gaap	Reinsurance Retention Excess Retention Amount Reinsured Per Event ReinsuranceRetentionExcessRetentionAmountReinsuredPerEvent	5000000	usd
CY2023Q3	us-gaap	Contracts In Force Subject To Participation Through Reinsurance Percentage ContractsInForceSubjectToParticipationThroughReinsurancePercentage	0.55
CY2023Q3	lmnd	Reinsurance Per Risk Limit Amount ReinsurancePerRiskLimitAmount	750000	usd
CY2023Q3	us-gaap	Reinsurance Retention Policy Excess Retention Percentage ReinsuranceRetentionPolicyExcessRetentionPercentage	1
CY2022Q3	us-gaap	Reinsurance Retention Policy Reinsured Risk Percentage ReinsuranceRetentionPolicyReinsuredRiskPercentage	0.30
CY2022Q3	lmnd	Reinsurance Program Minimum Losses Threshold ReinsuranceProgramMinimumLossesThreshold	80000000	usd
CY2023Q3	us-gaap	Reinsurance Retention Amount Retained Per Event ReinsuranceRetentionAmountRetainedPerEvent	50000000000000	usd
CY2023Q3	us-gaap	Reinsurance Retention Excess Retention Amount Reinsured Per Event ReinsuranceRetentionExcessRetentionAmountReinsuredPerEvent	80000000	usd
CY2024Q2	lmnd	Accrued Ceded Commissions AccruedCededCommissions	25400000	usd
CY2023Q4	lmnd	Accrued Ceded Commissions AccruedCededCommissions	13900000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	23400000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	28200000	usd
CY2024Q2	lmnd	Liability For Uncertainty In Income Taxes LiabilityForUncertaintyInIncomeTaxes	16400000	usd
CY2023Q4	lmnd	Liability For Uncertainty In Income Taxes LiabilityForUncertaintyInIncomeTaxes	13300000	usd
CY2024Q2	us-gaap	Accrued Advertising Current And Noncurrent AccruedAdvertisingCurrentAndNoncurrent	11100000	usd
CY2023Q4	us-gaap	Accrued Advertising Current And Noncurrent AccruedAdvertisingCurrentAndNoncurrent	6200000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	7500000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	8400000	usd
CY2024Q2	lmnd	Premium Taxes Payable PremiumTaxesPayable	5000000.0	usd
CY2023Q4	lmnd	Premium Taxes Payable PremiumTaxesPayable	5900000	usd
CY2024Q2	lmnd	Advance Premium Liability AdvancePremiumLiability	4500000	usd
CY2023Q4	lmnd	Advance Premium Liability AdvancePremiumLiability	3400000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	4400000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	5000000.0	usd
CY2024Q2	us-gaap	Reinsurance Payable ReinsurancePayable	4300000	usd
CY2023Q4	us-gaap	Reinsurance Payable ReinsurancePayable	800000	usd
CY2024Q2	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	2000000.0	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	1200000	usd
CY2024Q2	us-gaap	Other Sundry Liabilities OtherSundryLiabilities	17200000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities OtherSundryLiabilities	13200000	usd
CY2024Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	121200000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	99500000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71002862	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71002862	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70163703	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70163703	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9595257	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.26
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M15D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10300000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	782107	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.07
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	29473	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	359326	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	39.74
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9988565	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.60
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y18D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10990000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5156136	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	30.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y18D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	9600000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4832429	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	41.47
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M9D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1390000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15400000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14800000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30300000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30200000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15400000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14800000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30300000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30200000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.042
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.018
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	15700000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9600000	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	700000	usd
CY2023Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	100000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-57200000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-57200000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-67200000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67200000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-104500000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-104500000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-133000000.0	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-133000000.0	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70721227	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70721227	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69534731	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69534731	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70502856	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70502856	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	69434971	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	69434971	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.97
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.97
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.48
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.92
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.92
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14730584	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12970558	shares
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	300000	usd
CY2024Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	300000	usd
CY2024Q2	us-gaap	Premiums Written Gross PremiumsWrittenGross	226200000	usd
CY2023Q2	us-gaap	Premiums Written Gross PremiumsWrittenGross	181900000	usd
	us-gaap	Premiums Written Gross PremiumsWrittenGross	431800000	usd
	us-gaap	Premiums Written Gross PremiumsWrittenGross	345900000	usd
CY2024Q2	ecd	Trd Arr Expiration Date TrdArrExpirationDate	December 31, 2024
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001691421-24-000108-index-headers.html	Edgar Link	pending
0001691421-24-000108-index.html	Edgar Link	pending
0001691421-24-000108.txt	Edgar Link	pending
0001691421-24-000108-xbrl.zip	Edgar Link	pending
exhibit101-gcaragreement.htm	Edgar Link	pending
exhibit101-gcaragreement001.jpg	Edgar Link	pending
exhibit101-gcaragreement002.jpg	Edgar Link	pending
exhibit101-gcaragreement003.jpg	Edgar Link	pending
exhibit101-gcaragreement004.jpg	Edgar Link	pending
exhibit101-gcaragreement005.jpg	Edgar Link	pending
exhibit101-gcaragreement006.jpg	Edgar Link	pending
exhibit101-gcaragreement007.jpg	Edgar Link	pending
exhibit101-gcaragreement008.jpg	Edgar Link	pending
exhibit101-gcaragreement009.jpg	Edgar Link	pending
exhibit101-gcaragreement010.jpg	Edgar Link	pending
exhibit101-gcaragreement011.jpg	Edgar Link	pending
exhibit101-gcaragreement012.jpg	Edgar Link	pending
exhibit101-gcaragreement013.jpg	Edgar Link	pending
exhibit101-gcaragreement014.jpg	Edgar Link	pending
exhibit101-gcaragreement015.jpg	Edgar Link	pending
exhibit101-gcaragreement016.jpg	Edgar Link	pending
exhibit101-gcaragreement017.jpg	Edgar Link	pending
exhibit101-gcaragreement018.jpg	Edgar Link	pending
exhibit101-gcaragreement019.jpg	Edgar Link	pending
exhibit101-gcaragreement020.jpg	Edgar Link	pending
exhibit101-gcaragreement021.jpg	Edgar Link	pending
exhibit101-gcaragreement022.jpg	Edgar Link	pending
exhibit101-gcaragreement023.jpg	Edgar Link	pending
exhibit101-gcaragreement024.jpg	Edgar Link	pending
exhibit101-gcaragreement025.jpg	Edgar Link	pending
exhibit101-gcaragreement026.jpg	Edgar Link	pending
exhibit101-gcaragreement027.jpg	Edgar Link	pending
exhibit101-gcaragreement028.jpg	Edgar Link	pending
exhibit101-gcaragreement029.jpg	Edgar Link	pending
exhibit101-gcaragreement030.jpg	Edgar Link	pending
exhibit101-gcaragreement031.jpg	Edgar Link	pending
exhibit101-gcaragreement032.jpg	Edgar Link	pending
exhibit101-gcaragreement033.jpg	Edgar Link	pending
exhibit101-gcaragreement034.jpg	Edgar Link	pending
exhibit101-gcaragreement035.jpg	Edgar Link	pending
exhibit101-gcaragreement036.jpg	Edgar Link	pending
exhibit101-gcaragreement037.jpg	Edgar Link	pending
exhibit101-gcaragreement038.jpg	Edgar Link	pending
exhibit102-pprcontractju.htm	Edgar Link	pending
exhibit102-pprcontractju001.jpg	Edgar Link	pending
exhibit102-pprcontractju002.jpg	Edgar Link	pending
exhibit102-pprcontractju003.jpg	Edgar Link	pending
exhibit102-pprcontractju004.jpg	Edgar Link	pending
exhibit102-pprcontractju005.jpg	Edgar Link	pending
exhibit102-pprcontractju006.jpg	Edgar Link	pending
exhibit102-pprcontractju007.jpg	Edgar Link	pending
exhibit102-pprcontractju008.jpg	Edgar Link	pending
exhibit102-pprcontractju009.jpg	Edgar Link	pending
exhibit102-pprcontractju010.jpg	Edgar Link	pending
exhibit102-pprcontractju011.jpg	Edgar Link	pending
exhibit102-pprcontractju012.jpg	Edgar Link	pending
exhibit102-pprcontractju013.jpg	Edgar Link	pending
exhibit102-pprcontractju014.jpg	Edgar Link	pending
exhibit102-pprcontractju015.jpg	Edgar Link	pending
exhibit102-pprcontractju016.jpg	Edgar Link	pending
exhibit102-pprcontractju017.jpg	Edgar Link	pending
exhibit102-pprcontractju018.jpg	Edgar Link	pending
exhibit102-pprcontractju019.jpg	Edgar Link	pending
exhibit102-pprcontractju020.jpg	Edgar Link	pending
exhibit102-pprcontractju021.jpg	Edgar Link	pending
exhibit102-pprcontractju022.jpg	Edgar Link	pending
exhibit102-pprcontractju023.jpg	Edgar Link	pending
exhibit102-pprcontractju024.jpg	Edgar Link	pending
exhibit102-pprcontractju025.jpg	Edgar Link	pending
exhibit102-pprcontractju026.jpg	Edgar Link	pending
exhibit102-pprcontractju027.jpg	Edgar Link	pending
exhibit102-pprcontractju028.jpg	Edgar Link	pending
exhibit102-pprcontractju029.jpg	Edgar Link	pending
exhibit102-pprcontractju030.jpg	Edgar Link	pending
exhibit102-pprcontractju031.jpg	Edgar Link	pending
exhibit102-pprcontractju032.jpg	Edgar Link	pending
exhibit102-pprcontractju033.jpg	Edgar Link	pending
exhibit102-pprcontractju034.jpg	Edgar Link	pending
exhibit102-pprcontractju035.jpg	Edgar Link	pending
exhibit102-pprcontractju036.jpg	Edgar Link	pending
exhibit102-pprcontractju037.jpg	Edgar Link	pending
exhibit102-pprcontractju038.jpg	Edgar Link	pending
exhibit102-pprcontractju039.jpg	Edgar Link	pending
exhibit102-pprcontractju040.jpg	Edgar Link	pending
exhibit102-pprcontractju041.jpg	Edgar Link	pending
exhibit102-pprcontractju042.jpg	Edgar Link	pending
exhibit102-pprcontractju043.jpg	Edgar Link	pending
exhibit102-pprcontractju044.jpg	Edgar Link	pending
exhibit102-pprcontractju045.jpg	Edgar Link	pending
exhibit102-pprcontractju046.jpg	Edgar Link	pending
exhibit103-wqshannoverju.htm	Edgar Link	pending
exhibit103-wqshannoverju001.jpg	Edgar Link	pending
exhibit103-wqshannoverju002.jpg	Edgar Link	pending
exhibit103-wqshannoverju003.jpg	Edgar Link	pending
exhibit103-wqshannoverju004.jpg	Edgar Link	pending
exhibit103-wqshannoverju005.jpg	Edgar Link	pending
exhibit103-wqshannoverju006.jpg	Edgar Link	pending
exhibit103-wqshannoverju007.jpg	Edgar Link	pending
exhibit103-wqshannoverju008.jpg	Edgar Link	pending
exhibit103-wqshannoverju009.jpg	Edgar Link	pending
exhibit103-wqshannoverju010.jpg	Edgar Link	pending
exhibit103-wqshannoverju011.jpg	Edgar Link	pending
exhibit103-wqshannoverju012.jpg	Edgar Link	pending
exhibit103-wqshannoverju013.jpg	Edgar Link	pending
exhibit103-wqshannoverju014.jpg	Edgar Link	pending
exhibit103-wqshannoverju015.jpg	Edgar Link	pending
exhibit103-wqshannoverju016.jpg	Edgar Link	pending
exhibit103-wqshannoverju017.jpg	Edgar Link	pending
exhibit103-wqshannoverju018.jpg	Edgar Link	pending
exhibit103-wqshannoverju019.jpg	Edgar Link	pending
exhibit103-wqshannoverju020.jpg	Edgar Link	pending
exhibit103-wqshannoverju021.jpg	Edgar Link	pending
exhibit103-wqshannoverju022.jpg	Edgar Link	pending
exhibit103-wqshannoverju023.jpg	Edgar Link	pending
exhibit103-wqshannoverju024.jpg	Edgar Link	pending
exhibit103-wqshannoverju025.jpg	Edgar Link	pending
exhibit103-wqshannoverju026.jpg	Edgar Link	pending
exhibit103-wqshannoverju027.jpg	Edgar Link	pending
exhibit103-wqshannoverju028.jpg	Edgar Link	pending
exhibit103-wqshannoverju029.jpg	Edgar Link	pending
exhibit103-wqshannoverju030.jpg	Edgar Link	pending
exhibit103-wqshannoverju031.jpg	Edgar Link	pending
exhibit103-wqshannoverju032.jpg	Edgar Link	pending
exhibit103-wqshannoverju033.jpg	Edgar Link	pending
exhibit103-wqshannoverju034.jpg	Edgar Link	pending
exhibit103-wqshannoverju035.jpg	Edgar Link	pending
exhibit103-wqshannoverju036.jpg	Edgar Link	pending
exhibit103-wqshannoverju037.jpg	Edgar Link	pending
exhibit103-wqshannoverju038.jpg	Edgar Link	pending
exhibit103-wqshannoverju039.jpg	Edgar Link	pending
exhibit103-wqshannoverju040.jpg	Edgar Link	pending
exhibit103-wqshannoverju041.jpg	Edgar Link	pending
exhibit103-wqshannoverju042.jpg	Edgar Link	pending
exhibit103-wqshannoverju043.jpg	Edgar Link	pending
exhibit103-wqshannoverju044.jpg	Edgar Link	pending
exhibit103-wqshannoverju045.jpg	Edgar Link	pending
exhibit103-wqshannoverju046.jpg	Edgar Link	pending
exhibit103-wqshannoverju047.jpg	Edgar Link	pending
exhibit103-wqshannoverju048.jpg	Edgar Link	pending
exhibit103-wqshannoverju049.jpg	Edgar Link	pending
exhibit103-wqshannoverju050.jpg	Edgar Link	pending
exhibit103-wqshannoverju051.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly.htm	Edgar Link	pending
exhibit104-wqsmapfrejuly001.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly002.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly003.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly004.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly005.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly006.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly007.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly008.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly009.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly010.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly011.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly012.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly013.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly014.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly015.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly016.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly017.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly018.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly019.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly020.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly021.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly022.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly023.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly024.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly025.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly026.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly027.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly028.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly029.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly030.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly031.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly032.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly033.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly034.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly035.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly036.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly037.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly038.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly039.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly040.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly041.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly042.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly043.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly044.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly045.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly046.jpg	Edgar Link	pending
exhibit104-wqsmapfrejuly047.jpg	Edgar Link	pending
exhibit105-wqsswissrejul.htm	Edgar Link	pending
exhibit105-wqsswissrejul001.jpg	Edgar Link	pending
exhibit105-wqsswissrejul002.jpg	Edgar Link	pending
exhibit105-wqsswissrejul003.jpg	Edgar Link	pending
exhibit105-wqsswissrejul004.jpg	Edgar Link	pending
exhibit105-wqsswissrejul005.jpg	Edgar Link	pending
exhibit105-wqsswissrejul006.jpg	Edgar Link	pending
exhibit105-wqsswissrejul007.jpg	Edgar Link	pending
exhibit105-wqsswissrejul008.jpg	Edgar Link	pending
exhibit105-wqsswissrejul009.jpg	Edgar Link	pending
exhibit105-wqsswissrejul010.jpg	Edgar Link	pending
exhibit105-wqsswissrejul011.jpg	Edgar Link	pending
exhibit105-wqsswissrejul012.jpg	Edgar Link	pending
exhibit105-wqsswissrejul013.jpg	Edgar Link	pending
exhibit105-wqsswissrejul014.jpg	Edgar Link	pending
exhibit105-wqsswissrejul015.jpg	Edgar Link	pending
exhibit105-wqsswissrejul016.jpg	Edgar Link	pending
exhibit105-wqsswissrejul017.jpg	Edgar Link	pending
exhibit105-wqsswissrejul018.jpg	Edgar Link	pending
exhibit105-wqsswissrejul019.jpg	Edgar Link	pending
exhibit105-wqsswissrejul020.jpg	Edgar Link	pending
exhibit105-wqsswissrejul021.jpg	Edgar Link	pending
exhibit105-wqsswissrejul022.jpg	Edgar Link	pending
exhibit105-wqsswissrejul023.jpg	Edgar Link	pending
exhibit105-wqsswissrejul024.jpg	Edgar Link	pending
exhibit105-wqsswissrejul025.jpg	Edgar Link	pending
exhibit105-wqsswissrejul026.jpg	Edgar Link	pending
exhibit105-wqsswissrejul027.jpg	Edgar Link	pending
exhibit105-wqsswissrejul028.jpg	Edgar Link	pending
exhibit105-wqsswissrejul029.jpg	Edgar Link	pending
exhibit105-wqsswissrejul030.jpg	Edgar Link	pending
exhibit105-wqsswissrejul031.jpg	Edgar Link	pending
exhibit105-wqsswissrejul032.jpg	Edgar Link	pending
exhibit105-wqsswissrejul033.jpg	Edgar Link	pending
exhibit105-wqsswissrejul034.jpg	Edgar Link	pending
exhibit105-wqsswissrejul035.jpg	Edgar Link	pending
exhibit105-wqsswissrejul036.jpg	Edgar Link	pending
exhibit105-wqsswissrejul037.jpg	Edgar Link	pending
exhibit105-wqsswissrejul038.jpg	Edgar Link	pending
exhibit105-wqsswissrejul039.jpg	Edgar Link	pending
exhibit105-wqsswissrejul040.jpg	Edgar Link	pending
exhibit105-wqsswissrejul041.jpg	Edgar Link	pending
exhibit105-wqsswissrejul042.jpg	Edgar Link	pending
exhibit105-wqsswissrejul043.jpg	Edgar Link	pending
exhibit105-wqsswissrejul044.jpg	Edgar Link	pending
exhibit105-wqsswissrejul045.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lmnd-20240630.htm	Edgar Link	pending
lmnd-20240630.xsd	Edgar Link	pending
lmnd-20240630x10qxex311.htm	Edgar Link	pending
lmnd-20240630x10qxex312.htm	Edgar Link	pending
lmnd-20240630x10qxex321.htm	Edgar Link	pending
lmnd-20240630x10qxex322.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
lmnd-20240630_cal.xml	Edgar Link	unprocessable
lmnd-20240630_def.xml	Edgar Link	unprocessable
lmnd-20240630_lab.xml	Edgar Link	unprocessable
lmnd-20240630_pre.xml	Edgar Link	unprocessable
lmnd-20240630_htm.xml	Edgar Link	completed
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LMND
Lemonade Inc Stock $lmnd

2024 Q3 Form 10-Q Financial Statement

#000169142124000108 Filed on July 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LMND Lemonade Inc Stock $lmnd

2024 Q3 Form 10-Q Financial Statement

#000169142124000108 Filed on July 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LMND
Lemonade Inc Stock $lmnd